HGSI's Albuferon for hepatitis C advancing

March 14, 2006 at 11:09 AM

ROCKVILLE, Md., March 14 (UPI) -- Human Genome Sciences said its hepatitis C treatment Albuferon showed strong anti-viral activity in phase 2 trials.

David Stump, HGSI's executive vice president of drug development, said the company's phase 3 trials could be launched by the end of the year.

In the phase 2 study, 30 percent of the patients in the lower-dose treatment groups did not have detectable levels of the hepatitis C virus at the end of treatment, or week 48. This percentage dropped to 18 percent at the 12-week follow-up. HGSI said they considered the data positive because nearly two-thirds of the study participants had failed on previous treatment regimens.

In a phase 2b trial in interferon alpha-naive patients, Albuferon showed a trend toward being comparable to Pegasys with less frequent dosing. Approximately 75 percent of patients receiving Albuferon every 2 weeks exhibited a level of hepatitis C viral load below the level of quantitation at 12 weeks, compared with 66 percent of patients receiving Pegasys at seven-day intervals.

Like Us on Facebook for more stories from UPI.com  
Latest Headlines
Top Stories
Elastic gel stops bleeding, helps wounds heal
FDA to look at risks of treating children with codeine
Device helps doctors personalize chemotherapy for patients